Autoinflammation and HLA-B27: Beyond Antigen Presentation

REFERENCES

• McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133–144.
   PubMed Web of Science ®Google Scholar
• McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Medicine. 2006;3:e297.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol. 2011;41:1203–1217.
   PubMed Web of Science ®Google Scholar
• P. Matzinger Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.
   PubMed Web of Science ®Google Scholar
• Pradeu T, Cooper EL. The danger theory: 20 years later. Front Immunol. 2012;3:287.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–295.
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Coyne CB, et al. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev. 2012;249:158–175.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29:301–305.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46:3340–3348.
   PubMed Web of Science ®Google Scholar
• Henderson C, Goldbach-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol. 2010;22:567–578.
   PubMed Web of Science ®Google Scholar
• Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease (NOMID) treated with anakinra. Arthritis Rheum. 2012;64:2375–2386.
   PubMed Web of Science ®Google Scholar
• Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62:258–267.
   PubMed Web of Science ®Google Scholar
• Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997;90:797–807.
   PubMedGoogle Scholar
• A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25–31.
   PubMed Web of Science ®Google Scholar
• Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc. 1997;72:611–615.
   PubMed Web of Science ®Google Scholar
• Dugan J, Griffiths E, Snow P, et al. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice. J Immunol. 2015;194:349–357.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426–2437.
   PubMed Web of Science ®Google Scholar
• Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009;360:2438–2444.
   PubMed Web of Science ®Google Scholar
• Stolwijk C, Essers I, van Tubergen A, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2015;74:1373–1378.
   PubMed Web of Science ®Google Scholar
• Brown MA, Pile KD, Kennedy LG, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis. 1996;55:268–270.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Hirsch R, Dillon CF, et al. The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum. 2012;64:1407–1411.
   PubMed Web of Science ®Google Scholar
• Madden DR, Gorga JC, Strominger JL, et al. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell. 1992;70:1035–1048.
   PubMed Web of Science ®Google Scholar
• Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63:1099–1112.
   PubMed Web of Science ®Google Scholar
• Tran TM, Dorris ML, Satumtira N, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum. 2006;54:1317–1327.
   PubMed Web of Science ®Google Scholar
• Rosenbaum, et al. Endotoxin-induced uveitis in rats as a model for human disease. J Nature. 1980;Aug 7;286(5773);611–3.
   PubMed Web of Science ®Google Scholar
• Hermann E, Yu DT, Meyer zum Buschenfelde KH, et al. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet. 1993;342:646–650.
   PubMed Web of Science ®Google Scholar
• May E, Dorris ML, Satumtira N, et al. CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J Immunol. 2003;170:1099–1105.
   PubMed Web of Science ®Google Scholar
• Taurog JD, Dorris ML, Satumtira N, et al. Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8. Arthritis Rheum. 2009;60:1977–1984.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Baerlecken N, Witte T, et al. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis. 2014;73:1079–1082.
   PubMed Web of Science ®Google Scholar
• Tsui FW, Tsui HW, Las Heras F, et al. Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis. 2014;73:1873–1879.
   PubMed Web of Science ®Google Scholar
• Allen RL, O’Callaghan CA, McMichael AJ, et al. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol. 1999;162:5045–5048.
   PubMed Web of Science ®Google Scholar
• Kollnberger S, Bowness P. The role of B27 heavy chain dimer immune receptor interactions in spondyloarthritis. Adv Exp Med Biol. 2009;649:277–285.
   PubMed Web of Science ®Google Scholar
• Jiao YL, Zhang BC, You L, et al. Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. J Clin Immunol. 2010;30:840–844.
   PubMed Web of Science ®Google Scholar
• Diaz-Pena R, Vidal-Castineira JR, Alonso-Arias R, et al. Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis. Arthritis Rheum. 2010;62:1000–1006.
   PubMed Web of Science ®Google Scholar
• Fan D, Liu S, Yang T, et al. Association between KIR polymorphisms and ankylosing spondylitis in populations: a meta-analysis. Mod Rheumatol. 2014;24:985–991.
   PubMed Web of Science ®Google Scholar
• Ambarus C, Yeremenko N, Tak PP, et al. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr Opin Rheumatol. 2012;24:351–358.
   PubMed Web of Science ®Google Scholar
• Mear JP, Schreiber KL, Munz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol. 1999;163:6665–6670.
   PubMed Web of Science ®Google Scholar
• Turner MJ, Delay ML, Bai S, et al. HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: Implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum. 2007;56:215–223.
   PubMed Web of Science ®Google Scholar
• DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633–2643.
   PubMed Web of Science ®Google Scholar
• Smith JA, Turner MJ, DeLay ML, et al. Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-beta induction via X-box binding protein 1. Eur J Immunol. 2008;38:1194–1203.
   PubMed Web of Science ®Google Scholar
• Layh-Schmitt G, Yang EY, Kwon G, et al. HLA-B27 alters the response to tumor necrosis factor alpha and promotes osteoclastogenesis in bone marrow monocytes from HLA-B27-transgenic rats. Arthritis Rheum. 2013;65:2123–2131.
   PubMed Web of Science ®Google Scholar
• Gu J, Rihl M, Marker-Hermann E, et al. Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J Rheumatol. 2002;29:2159–2164.
   PubMed Web of Science ®Google Scholar
• Feng Y, Ding J, CM Fan, et al. Interferon-gamma contributes to HLA-B27-associated unfolded protein response in spondyloarthropathies. J Rheumatol. 2012;39:574–582.
   PubMed Web of Science ®Google Scholar
• Neerinckx B, Carter S, Lories RJ. No evidence for a critical role of the unfolded protein response in synovium and blood of patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73:629–630.
   PubMed Web of Science ®Google Scholar
• Murrow L, Debnath J. Autophagy as a stress response and quality control mechanism – implications for cell injury and human disease. Annu Rev Pathol. 2013;8:105–137.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Accardo-Palumbo A, Rizzo A, et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis. 2014;73:1566–1574.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Sims AM, Danoy P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010;42:123–127.
   PubMed Web of Science ®Google Scholar
• Evans DM, Spencer CCA, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43:761–767.
   PubMed Web of Science ®Google Scholar
• Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45:730–738.
   PubMed Web of Science ®Google Scholar
• Various associations. Association scan of 14,500 nsSNPs in four common diseases identifies variants involved in autoimmunity. Nat Genet. 2007;39:1329–1337.
   PubMed Web of Science ®Google Scholar
• Robinson PC, Claushuis TA, Cortes A, et al. Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol. 2015;67:140–151.
   PubMed Web of Science ®Google Scholar
• Hüffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet. 2010;42:996–999.
   PubMed Web of Science ®Google Scholar
• Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet. 2010;42:1000–1004.
   PubMed Web of Science ®Google Scholar
• Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008;4:e1000041.
   PubMed Web of Science ®Google Scholar
• Bowes J, Budu-Aggrey A, Huffmeier U, et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun. 2015;6:6046.
   PubMed Web of Science ®Google Scholar
• Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40:1823–1828.
   PubMed Web of Science ®Google Scholar
• Evans DM, Spencer CC, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43:761–767.
   PubMed Web of Science ®Google Scholar
• Bowes J, Loehr S, Budu-Aggrey A, et al. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Ann Rheum Dis. 2015;74:1882–1885.
   PubMed Web of Science ®Google Scholar
• Apel M, Uebe S, Bowes J, et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum. 2013;65:1224–1231.
   PubMed Web of Science ®Google Scholar
• Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Current allergy and asthma reports. 2015;15:489.
   PubMed Web of Science ®Google Scholar
• Bowes J, Budu-Aggrey A, Huffmeier U, et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun 2015;6:6046.
   PubMed Web of Science ®Google Scholar
• Gill T, Asquith M, Rosenbaum JT, et al. The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol. 2015;27:319–325.
   PubMed Web of Science ®Google Scholar
• Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359–2364.
   PubMed Web of Science ®Google Scholar
• Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Investig. 1996;98:945–953.
   PubMed Web of Science ®Google Scholar
• Lin P, Bach M, Asquith M, et al. HLA-B27 and human beta2-microglobulin affect the gut microbiota of transgenic rats. PloS One. 2014;9:e105684.
   PubMed Web of Science ®Google Scholar
• Costello ME, Ciccia F, Willner D, et al. Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol 2014. DOI:10.1002/art.38967.
   PubMed Web of Science ®Google Scholar
• Kvien TK, Glennas A, Melby K, et al. Reactive arthritis: incidence, triggering agents and clinical presentation. J Rheumatol. 1994;21:115–122.
   PubMed Web of Science ®Google Scholar
• Merilahti-Palo R, Soderstrom KO, Lahesmaa-Rantala R, et al. Bacterial antigens in synovial biopsy specimens in Yersinia triggered reactive arthritis. Ann Rheum Dis. 1991;50:87–90.
   PubMed Web of Science ®Google Scholar
• Granfors K, Jalkanen S, Lindberg AA, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet. 1990;335:685–688.
   PubMed Web of Science ®Google Scholar
• Mielants H, Veys EM, Cuvelier C, et al. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol. 1985;12:294–298.
   PubMed Web of Science ®Google Scholar
• Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;73:1186–1189.
   PubMed Web of Science ®Google Scholar
• Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol. 2014;26:361–370.
   PubMed Web of Science ®Google Scholar
• Becker C, Wirtz S, Blessing M, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Investig. 2003;112:693–706.
   PubMed Web of Science ®Google Scholar
• Zeng L, Lindstrom MJ, Smith JA. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum. 2011;63:3807–3817.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Bleil J, et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum. 2013;65:1522–1529.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2009;60:955–965.
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125–130.
   PubMed Web of Science ®Google Scholar
• Kopp T, Lenz P, Bello-Fernandez C, et al. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol. 2003;170:5438–5444.
   PubMed Web of Science ®Google Scholar
• Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma/delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64:1420–1429.
   PubMed Web of Science ®Google Scholar
• Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58:2307–2317.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Investig Dermatol. 2008;128:1207–1211.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1–2):419–429.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8-entheseal resident T cells. Nat Med. 2012;18:1069–1076.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:1739–1747.
   PubMed Web of Science ®Google Scholar
• Wendling D, Dougados M, Berenbaum F, et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol. 2012;39:2327–2331.
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62:1290–1297.
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70:1108–1110.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–128.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780–789.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990–999.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386:1137–1146.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–1713.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817–823.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777–787.
   PubMed Web of Science ®Google Scholar
• Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014;65:223–244.
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64:296–298.
   PubMed Web of Science ®Google Scholar
• Tan AL, Marzo-Ortega H, O’Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis. 2004;63:1041–1045.
   PubMed Web of Science ®Google Scholar
• Bennett AN, Tan AL, Coates LC, et al. Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:223–224.
   PubMed Web of Science ®Google Scholar
• Planck SR, Woods A, Clowers JS, et al. Impact of IL-1 signalling on experimental uveitis and arthritis. Ann Rheum Dis. 2012;71:753–760.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Aydin SZ, Gul A, et al. ‘MHC-I-opathy’-unified concept for spondyloarthritis and Behçet disease. Nature reviews. Rheumatology. 2015;11:731–740.
   PubMed Web of Science ®Google Scholar